Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Observational

Clinical Performance of QIAstat-Dx® Meningitis/Encephalitis (ME) Panel Plus

NCT06820060 · tracked via the Priya Life Science UK tracker
Phase
Observational
Started
2025-04-03
Last updated
2026-07-31

Condition(s) studied

MeningitisEncephalitis Infection

Study summary

Performance evaluation of QIAstat-Dx® ME Panel Plus using the QIAstat-Dx® Analyzer to demonstrate that the QIAstat-Dx® ME Panel Plus achieves its intended performance during normal conditions of use by the intended user in the intended environment

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Specimen must be Cerebrospinal fluid, obtained via lumbar puncture only. * Specimen must be a de-identified residual leftover specimen. * Specimen must meet the laboratory testing criteria for individuals with signs and/or symptoms of meningitis and/or encephalitis. * Specimens must have a minimum 450 µL of residual volume. * Specimen must be unique (only one sample enrolled per patient). * Prior to QIAstat-Dx testing, residual CSF specimen must have been stored in accordance with the following: * Prospective Fresh: * Room temperature (15 °C to 25 °C) for ≤24 hrs * Refrigerated (2 °C to 8 °C) for ≤ 7 days * Prospective Frozen: * -15 ºC to -25 ºC for ≤ 2 months * -60 ºC to -90 ºC for ≤ 4 months * Retrospective Archived: * Frozen * At the time of QIAstat-Dx testing, specimen must not have undergone more than three (3) freeze/thaw cycles. * Prospective Samples Only: Specimen must have been collected on or after the date of prospective study activation at the Clinical collection and testing site. * Retrospective Samples Only: Specimens must have a positive diagnosis as per Standard of Care for any of the following viral targets: Herpes simplex virus 1 (HSV-1) Herpes simplex virus 2 (HSV-2) Human herpesvirus 6 (HHV-6) Human parechovirus (HPeV) Varicella zoster virus (VZV) Cytomegalovirus (CMV) Exclusion Criteria: * Residual CSF specimen has been centrifuged. * Residual CSF specimen subject identification or label is unclear or missing. * Residual CSF specimen container has obvious physical damage.

Primary outcome measure(s)

  • PPA — 7 months
    Positive percent agreement
  • NPA — 7 months
    Negative percent agreement

Trial sites (1)

FacilityCityRegionStatus
QIAGEN Manchester United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06820060 on ClinicalTrials.gov ↗ ← All trials in the UK